$2.20
0.115.26%
Last update: 12:17 PM
15 minutes delayed
Processa Pharma
PCSANASDAQ
Processa Pharma (NASDAQ:PCSA) Stock, Analyst Ratings, Price Targets, Predictions
Processa Pharmaceuticals Inc has a consensus price target of $3.8, established from looking at the 11 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on June 12, 2024, May 13, 2024, and April 25, 2024. With an average price target of $8 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 300.00% upside for Processa Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Benchmark
Maxim Group
Benchmark
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Processa Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/12/2024 | Buy Now | 300% | HC Wainwright & Co. | Raghuram Selvaraju | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | 300% | HC Wainwright & Co. | Raghuram Selvaraju | → $8 | Reiterates | Buy → Buy | Get Alert |
| 04/25/2024 | Buy Now | 300% | HC Wainwright & Co. | Raghuram Selvaraju | → $8 | Initiates | → Buy | Get Alert |
| 03/06/2024 | Buy Now | 100% | Benchmark | Robert Wasserman | → $4 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 11/17/2023 | Buy Now | — | Maxim Group | Naz Rahman | — | Downgrade | Buy → Hold | Get Alert |
| 04/04/2023 | Buy Now | 100% | Benchmark | Aydin Huseynov | $180 → $80 | Maintains | Speculative Buy | Get Alert |
| 04/03/2023 | Buy Now | 50% | Oppenheimer | Francois Brisebois | $100 → $60 | Maintains | Outperform | Get Alert |
| 01/12/2023 | Buy Now | 150% | Maxim Group | Naz Rahman | $180 → $100 | Maintains | Buy | Get Alert |
| 04/19/2022 | Buy Now | 350% | Maxim Group | Naz Rahman | → $180 | Initiates | → Buy | Get Alert |
| 08/03/2021 | Buy Now | 900% | Oppenheimer | Francois Brisebois | → $400 | Initiates | → Outperform | Get Alert |
| 08/02/2021 | Buy Now | 900% | Oppenheimer | Francois Brisebois | → $400 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Processa Pharma (PCSA) stock?
The latest price target for Processa Pharma (NASDAQ:PCSA) was reported by HC Wainwright & Co. on June 12, 2024. The analyst firm set a price target for $8.00 expecting PCSA to rise to within 12 months (a possible 263.64% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Processa Pharma (PCSA)?
The latest analyst rating for Processa Pharma (NASDAQ:PCSA) was provided by HC Wainwright & Co., and Processa Pharma reiterated their buy rating.
When was the last upgrade for Processa Pharma (PCSA)?
There is no last upgrade for Processa Pharma
When was the last downgrade for Processa Pharma (PCSA)?
The last downgrade for Processa Pharmaceuticals Inc happened on November 17, 2023 when Maxim Group changed their price target from N/A to N/A for Processa Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Processa Pharma (PCSA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Processa Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Processa Pharma was filed on June 12, 2024 so you should expect the next rating to be made available sometime around June 12, 2025.
Is the Analyst Rating Processa Pharma (PCSA) correct?
While ratings are subjective and will change, the latest Processa Pharma (PCSA) rating was a reiterated with a price target of $8.00 to $8.00. The current price Processa Pharma (PCSA) is trading at is $2.20, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.